Germany’s medicines regulator BfArM recently published the minutes of its most recent Expert Committee on Prescription meeting, at which the Rx-to-OTC switch of erectile dysfunction treatment sildenafil (50mg) was discussed.
The switch was rejected, this much we know from the “short notice” published in January immediately after the meeting. But with the summary minutes we know have some idea why the switch was unsuccessful
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?